2 1 Shi Ji Jing Ji Bao Dao·2025-07-02 08:38Core Viewpoint - The recent announcement by the Shanghai Medical Insurance Bureau regarding the adjustment of coronary stent reimbursement standards is expected to provide new ideas for diversified payment methods in the industry [1][5]. Group 1: Policy Changes - The new reimbursement rules categorize coronary stents into three payment categories: full reimbursement for selected products, a reduced maximum payment for non-selected products, and a percentage payment for products outside the selection [1][5]. - The policy aims to create a competitive environment for high-value innovative devices alongside selected products, potentially increasing their market presence [1][5]. Group 2: Market Impact - The shift in policy is seen as beneficial for non-selected products, allowing hospitals more freedom to use them after fulfilling procurement obligations for selected products [2][5]. - The coronary stent market has experienced significant price reductions due to centralized procurement, with average prices dropping from approximately 13,000 yuan to around 700 yuan [3][4]. Group 3: Industry Dynamics - The coronary intervention medical device sector is highly competitive, with domestic and international companies vying for market share through technological advancements and product offerings [6][7]. - Companies like Sientra have reported substantial growth in sales of their stent products, indicating a positive response to the new procurement policies [6][7]. Group 4: Future Outlook - The industry is expected to focus on innovation and international expansion as key strategies for growth, with companies exploring new business models and enhancing product lines [7][8]. - The global medical device market is substantial, with opportunities for Chinese companies to expand their presence internationally, driven by policy adjustments and technological advancements [8].